Studies on pyrazinoylguanidine

Pharmacology

Volumn 53, Issue 4, 1996, Pages 197-210

  A Rahim, Yousif I ^a   Beyer, Karl H ^a   Vesell, Elliot S ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Adipocytes; Cyclic AMP; Diabetes mellitus; Lipolysis; Pyrazinoylguanidine

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; FORSKOLIN; GLUCAGON; GUANIDINE DERIVATIVE; ISOPRENALINE; PYRAZINOYLGUANIDINE; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG;

ADIPOCYTE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME REGULATION; LIPOLYSIS; MALE; NONHUMAN; NUCLEIC ACID METABOLISM; PRIORITY JOURNAL; RAT;

ADIPOCYTES; ADRENERGIC BETA-AGONISTS; ANIMALS; CYCLIC AMP; DOWN-REGULATION; FORSKOLIN; GLYCEROL; GUANIDINES; HYPOGLYCEMIC AGENTS; ISOPROTERENOL; LIPASE; LIPOLYSIS; MALE; PERTUSSIS TOXIN; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; VIRULENCE FACTORS, BORDETELLA;

EID: 0029823191     PISSN: 00317012     EISSN: 14230313     Source Type: Journal    
DOI: 10.1159/000139431     Document Type: Article

References (30)

1. Fain JN: Biochemical aspects of drug and hormone action on adipose tissue, Pharmacol Rev 1973:25:67-118.
2. Sutherland EW: Studies on the mechanism of hormone action, Science 1972:177:401-408.
3. Stralfors P, Bjorgell P, Bcll'rage P: Hormonal regulation of hormone-sensitive lipase in intact adipocytes: Identification of phosphorvlated sites and effects on the phosphorylation by lipolytic hormones and insulin, Proc Natl Acad Sci USA 1984: 81:3317-3321.
4. Steinberg D: Catecholamine stimulation of fat mobilization and its metabolic consequences, Pharmacol Rev 1966:18:217-251.
5. Smigel M, Ferguson K, Gilman A: Control of adenylate cyclase activity by G proteins, Adv Cyclic Nucleotide Protein Phosphorylation Res 1985;19:103-111.
6. Fain J, Malbon C: Regulation of adenylate cyclase by adenosine, Mol Cell Biochcm 1979;25:143-169.
7. Ross E, Pedersen S, Florio V: Hormone-sensitive adenylate cyclase: Identity, function, and regulation of the protein components, Curr Top Membr Transport 1983:18:109-142.
8. Milligan G: Mechanisms of multifunctional signalling by G protein-linked receptors, Trends Pharmacol Sci 1993:14:239-244.
9. Reaven G, Chang H, Ho H, Jeng C, Hoffman B: Lowering of plasma glucose in diabetic rats by antilipolvtic agents, Am J Physiol 1988:254: E23-E30.
10. Bogardus C, Lillioja S, Howard B, Reaven G, Mott D: Relationship between insulin secretion, insulin action, and fasting plasma glucose concentration in nondiabetic and non-insulin-depcndcnt diabetic subjects, J Clin Invest 1984:74:1238-1246.
11. Vesell E, Chambers C, DeAngelo T, Passananti T, Demers L, Beyer K: Pvrazinoylguanidinc downregulates the glucose fatty-acid cycle in hypertensive, hyperinsulinémie diabetic patients, J Clin Pharmacol 1994:34: 1234-1245.
12. Vesell E, Chambers C, Passananti T, Demers L, Beyer K: Effects of pyra-zinoylguanidine on the glucosc-fattv acid cycle in normal subjects and patients with non-insulin-depen-dent diabetes mcllitus, J Clin Pharmacol 1993;33:823-831.
13. A-Rahim Y, Beyer K, Vesell E: Studies on pyrazinoylguanidinc, I, Characterization of metabolic effects in diabetic rats, Pharmacology 1996:52:135-144.
14. A-Rahim Y, Beyer K, Vesell E: Studies on pyrazinoylguanidinc, 2, Comparative drug and dose effects on glucose and lipid metabolism in streptozotocin-induced diabetic rats, Pharmacology 1996:52:145-152.
15. Beyer K, Gclardcn T: Active transport of urea by mammalian kidney, Proc Natl Acad Sci USA 1988:85: 4030-4031.
16. Beyer K, Gelarden T, Vary J, Brown L, Vesell E: Novel multivalent effects of pyrazinoylguanidinc in patients with azotemia, Clin Pharmacol Ther 1990:47:629-638.
17. Beyer K, Gelarden T, Vesell E: Inhibition of urea transport across renal tubules by pyrazinoylguanidinc and analogs, Pharmacology 1992:45: 129-141.
18. Chambers C, Vesell E, Helm C, Passananti T, Beyer K: Pyrazinoylgua-nidinc: Antihypertensive, hypocholestérolémie, and renin effects, J Clin Pharmacol 1992:32:1128-1134.
19. Beyer K, Ward T, Vary J, Gelarden T, Knutson D, Vesell H: Contrasting effects of pyrazinoylguanidine and hydrochlorothiazides in patients with renal insufficiency., J Clin Pharmacol 1993;33:554-561.
20. Passananti T, Vesell E, Jeszcnka E, Gelarden T, Beyer K: Pharmacokinetics of pyrazinoylguanidine, 3-aminopyrazinoylguanidinc and their corresponding pyrazinoic acid metabolites in humans and dogs, Pharmacology 1992;45:129-141.
21. Rodbell M: Metabolism of isolated fat cells, J Biol Chem 1964,239: 368-375.
22. Eggstein M, Kuhlman E: Triglycerides and glycerol; in Bergmeyer HV (ed): Methods of Enzymatic Analysis, Weinheim, Verlag Chemie, 1974, pp 1825-1831.
23. Parsons W, Stiles G: Heterologous desensitization of the inhibitory A adenosine receptor-adenylate cyclase system in rat adipocytes, J Biol Chem 1987;262:841-847
24. Ui M: Islet-activating protein, pertussis toxin: A probe for function of the inhibitory’ guanine nucleotide regulatory component of adenylate cyclase, Trends Pharmacol Sci 1984: 5:277-279.
25. Ribeiro-Neto F, Mattcra R, Hildebrand! J, Codina J, Field J, Bim-baumcr L, Sckura R: ADP-ribosyla-tion of membrane components by pertussis and cholera toxin, Methods Enzymol 1985;109:566-572.
26. Sunyer T, Monastirsky B, Codina J, Bimbaunter L: Studies on nucleotide and receptor regulation of G, proteins: Effects of pertussis toxin, Mol Endocrinol 1989:3:1115-1124.
27. Seamon K: Forskolin and adenylate cyclase: New opportunities in drug design, Annu Rep Med Chem 1984; 19:293-302.
28. A-Rahim Y, Rannels S, Kimball S, Beyer K, Vesell E: Studies on pyrazinoylguanidine, 4, Upregulation of phosphodiesterase activity in rat adipose tissue and downrcgula-tion of gluconeogenesis and adenosine 3',5'-monophosphate concentrations in perfused rat liver, Pharmacology 1996;53:211-218.
29. Stralfors P, Honnor R: Insulin-induced dephosphorylation of hormone-sensitive lipase, Eur J Bio-chent 1989;182:379-385.
30. Schwabe U, Ebert R: Different effects of lipolytic hormones and phosphodiesterase inhibitors on cyclic 3',5'-AMP concentrations in isolated fat cells, Naunyn-Schmicdc-berg’s Arch Pharmacol 1972:274: 287-298.